Trastuzumab, an anti-HER2 humanized monoclonal antibody [10], already in use for prolonging overall survival and progression-free survival in patients with HER2-positive breast cancer, has now been shown to significantly prolong survival in patients with GC and GEC. This evidence concerns the gene ERBB2 and gastric cancer.